Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Black Diamond Stock: Weighing Catalysts vs. Concentration
BDTX hinges on silevertinib's mutation breadth and CNS activity, with 2026 data, cash runway, and partnership moves set to shape its high-risk, high-reward path.
BDTX: What Silevertinib Data Say About EGFR NSCLC Upside
BDTX bets on silevertinib's broad EGFR mutation reach and CNS activity, but with no approved products, upcoming 2026 data and partnerships are pivotal.
Black Diamond Therapeutics: Market Is Yawning About These Data, But I See Opportunity
Black Diamond Therapeutics (BDTX) remains a 'Buy', as silevertinib shows promising efficacy in EGFR-mutant NSCLC with notable CNS activity. BDTX reported a 60% objective response rate and 86% CNS response rate in phase 2 silevertinib data, addressing key resistance mutations. Cash position supports operations into 2028, allowing BDTX to reach pivotal clinical catalysts before requiring additional funding.
Is Black Diamond Therapeutics (BDTX) Stock Outpacing Its Medical Peers This Year?
Here is how Black Diamond (BDTX) and Bionano Genomics, Inc. (BNGO) have performed compared to their sector so far this year.
What Makes Black Diamond (BDTX) a New Strong Buy Stock
Black Diamond (BDTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Down 30.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX)
Black Diamond (BDTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Black Diamond Therapeutics: Underappreciated Despite An Upcoming Key Readout
Black Diamond Therapeutics remains undervalued despite recent share price gains, with a promising EGFR inhibitor pipeline targeting unmet needs. Silevertinib, BDTX's lead candidate, is advancing in NSCLC and glioblastoma, with key clinical updates expected in late 2025 and early 2026. BDTX's financial position is strong, with a cash runway extending into Q4 2027, supported by a recent $70 million payment from Servier.
Black Diamond Therapeutics, Inc. (BDTX) Hits Fresh High: Is There Still Room to Run?
Black Diamond (BDTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Should You Buy, Hold, or Sell BDTX Stock Ahead of Q3 Earnings?
Black Diamond Therapeutics gears up for Q3 results as investors eye key silevertinib data and additional development plans.
BDTX vs. ORIC: Which Oncology Focused Biotech Stock Is a Better Pick Now?
ORIC's diversified oncology pipeline and positive estimate revisions give it an edge over BDTX's silevertinib-focused strategy.
BDTX Stock Hits 52 Week High: Is There More Room for Growth?
Black Diamonds shares surge 86.4% in 2025 as strong silevertinib data and rising estimates fuel optimism for further gains.
BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy?
BDTX and Cullinan advance next-gen EGFR inhibitors, but silevertinib's potential and valuation tilt momentum toward BDTX.
